Edgewise boosts R&D spending as drug trials bear promising results

BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX), a Boulder-based biopharmaceutical company that develops therapies for muscle disease, touted promising results in drug trials for several of its candidates in its first-quarter earnings report.

“With multiple near-term catalysts and a highly focused team, we are well positioned to advance our programs and deliver potentially transformative therapeutic options for patients facing serious muscle diseases facing high unmet need,” Edgewise CEO Kevin Koch said in a prepared statement.

Edgewise’s drug pipeline includes sevasemten, a fast-skeletal myosin inhibitor designed to protect against contractions-induced muscle damage in muscular dystrophies, and EDG-15400, a clinical candidate targeting heart failure.

Research and development expenses were $42.7 million in the most-recent period, up from $36.8 million in the first quarter of 2025. 

“The increase was primarily driven by increased clinical development activity related to EDG‑7500 and EDG‑15400, as well as higher internal personnel‑related costs to support the advancement of the Company’s clinical‑stage programs,” the earnings report said.

The company’s net loss grew from $40.8 million in the first quarter of last year to $49 million in the same period this year. 

To end the first quarter of fiscal 2026, Edgewise boasted $499.6 million in cash, cash equivalents and marketable securities.

Edgewise’s stock finished trading Thursday at $35.58, down 3.81% on the day.

Share on Facebook on LinkedIn